Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,649
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
stocks
Chart of the Week: The long term headwinds facing copper shares
stocks
Australia’s oldest REIT undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,048.30 | 74.60 | 0.83% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,350.03 | 295.00 | 1.28% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,744.07 | 1,010.92 | 1.47% |
| NZX 50 Index | 13,618.42 | 36.23 | 0.27% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,844.40 | 75.10 | 0.86% |
| SSE Composite Index | 4,043.64 | 14.74 | 0.37% |